RESULTS	At week 12 , ACR20 response rates for patients receiving all tofacitinib dosages 3 mg twice daily ( 52.9 % for 3 mg twice daily , 50.7 % for 5 mg twice daily , 58.1 % for 10 mg twice daily , 56.0 % for 15 mg twice daily , and 53.8 % for 20 mg/day ) were significantly ( P 0.05 ) greater than those for placebo ( 33.3 % ) .\